

Invega Sustenna® Review Questionnaire

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

3. What black box warning is associated with this medication?

4. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

5. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?

6. What would the *recommended* maintenance dosage be for the patient in #4?

7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 91mL/min?

8. What would the *recommended* maintenance dosage be for the patient in #6?

9. If the patient in #6 misses the second initiation dose and it has been 5 weeks since the first injection, what is the recommended protocol to resume dosing?

10. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

11. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

12. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.
